1 results found | searching for "CARTcellth0erapyMarketGrowth"

• 
• CAR-T Cell Therapy market Professional Survey Report by 2035 As the six approved CAR-T cell therapies, including Breyanzi®, Abecma™ and CARVYKTI™ are poised to achieve blockbuster status, along with a promising development pipeline, the field of CAR-T cell therapies has gained significant traction Roots Analysis is pleased to announce the publication of its recent study, titled, “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035.” The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:  A detailed assessment of the current market landscape of CAR-T-cell therapies.  An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors.  A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies.  An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies.  Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above).  An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies.  An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies.  An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022.  A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.  An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.  A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies.  Elaborate profiles of the several leading players in the domain of CAR-T cell therapies. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):  Target Indication(s)  Non-Hodgkin’s Lymphoma  Multiple Myeloma  Acute Lymphoblastic Leukemia  Chronic Lymphocytic Leukemia  Hodgkin’s Lymphoma  Acute Myeloid Leukemia  Ovarian Cancer  Generalized Myasthenia Gravis (MG)  Renal Cell Carcinoma  Target Antigen  CD19  BCMA  CD19/22  Others  Key Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa  Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companies:  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)  Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)  Miguel Forte (Chief Operating Officer, TxCell)  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), details about CAR-T-cell based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the players.  Autolus  bluebird Bio  Bristol Myers Squibb  Carsgen Therapeutics  Cellectis  Cellular Biomedicine Group  Gilead Sciences  Innovative Cellular Therapeutics  Kuur Therapeutics  Noile-Immune Biotech  Novartis  Shanghai GeneChem  Sinobioway Cell Therapy  Takara Bio  Wellington Zhaotai Therapies Get more details on the CAR-T Cell Therapy Market report https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html You may also be interested in the following titles: DNA Encoded Libraries Quantum Computing in Drug Discovery Services Market You may also like to learn what our experts are sharing in Roots educational series: mRNA Synthesis: Manufacturing Process of Modern Revolutionary Molecule TIL Therapies: A New Paradigm in Cancer Treatment About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #CARTcelltherapyMarket #CARTcelltherapyMarket Size #CARTcellth0erapyMarketGrowth #CARTcelltherapies #ChimericAntigenReceptor

  by jameshebrew,  Health 

  0 reply